Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2024

Discontinued Operations [Abstract]

Schedule of Financial Results of the ACO/MSO Division

The following table presents financial results of the ACO/MSO Division for the three and six months ended June 30, 2024 and 2023:

	Three Months Ended June 30,					Six Months Ended June 30,
	2024		2023			2024		2023
Revenue:
Consulting revenue	$	—	$	—		$	—	$	23,646
Total revenue		—		—			—		23,646
Operating Expenses and Costs:
Medicare shared savings expenses		—		14,452			—		82,387
Loss from operations of discontinued operations before income taxes		—		(14,452	)		—		(58,741	)
Provision for income taxes		—		—			—		—
Loss from discontinued operations, net of income taxes	$	—	$	(14,452	)	$	—	$	(58,741	)

Schedule of Fair Value of Consideration Received and Receivable

The fair value of consideration received and receivable is shown in the following table:

Upfront Cash Consideration paid at signing	$	750,000
Incremental Cash Consideration		1,311,567
IPO Share Consideration		1,463,517
2022 MSSP Consideration		312,987
Physician Advance Consideration		199,645
Stub Period Reimbursement		31,381
Total fair value of contingent consideration receivable		3,319,097
Total fair value of consideration received and receivable	$	4,069,097

Schedule of Assets and Liabilities Derecognized

The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows:

Prepaid expenses	$	1,500
Intangible asset - ACO physician contract		1,073,000
Goodwill		381,856
Contract liability		(20,278	)
Contingent acquisition consideration		(185,024	)
Net Book Value of Assets and Liabilities Sold	$	1,251,054

Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities

After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the six months ended June 30, 2023 as follows:

Total fair value of consideration received and receivable	$	4,069,097
Less: net book value of assets and liabilities sold		(1,251,054	)
Less: fair value of Indemnification Clause		(143,974	)
Gain from disposal of discontinued operations	$	2,674,069

Schedule of Remaining Unresolved Components of Contingent Consideration Receivable

The carrying value of the remaining unresolved components of contingent consideration receivable as of June 30, 2024 and December 31, 2023 was as follows:

IPO Share Consideration	$	1,463,518
Physician Advance Consideration		199,645
Remaining contingent sale consideration receivable	$	1,663,163